MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-18-2026
Virios Therapeutics, LLC Total Liabilities 2011-2026 | VIRI
Annual Total Liabilities Virios Therapeutics, LLC
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15.3 M | 30 M | 359 K | 1.04 M | 1.28 M | 1.53 M | 5.26 M | 1.33 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 30 M | 359 K | 7.01 M |
Quarterly Total Liabilities Virios Therapeutics, LLC
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.6 M | 14.2 M | 14.2 M | 30 M | 1.33 M | 500 K | - | 359 K | 487 K | 520 K | 549 K | 1.04 M | 1.63 M | 1.9 M | 1.88 M | 1.28 M | 1.23 M | 906 K | 1.17 M | 1.53 M | 1.53 M | 1.53 M | 1.53 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 30 M | 359 K | 4.27 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
1.76 B | $ 9.83 | 2.5 % | $ 636 M |  USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 98.36 | -4.92 % | $ 27.2 B | Germany |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 5.12 | 4.07 % | $ 820 M |  Britain |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | Britain |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B | France |
 |
Cerus Corporation
CERS
|
157 M | $ 2.57 | 26.6 % | $ 490 M | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
455 M | $ 21.92 | -2.38 % | $ 3.63 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Athira Pharma
ATHA
|
64.4 M | - | - | $ 269 M | USA |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Atreca
BCEL
|
76.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
84 M | - | -7.31 % | $ 87 M | USA |
 |
Calithera Biosciences
CALA
|
15.7 M | - | -10.95 % | $ 876 K | USA |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |
 |
ChemoCentryx
CCXI
|
140 M | - | - | $ 3.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Caladrius Biosciences
CLBS
|
5.68 M | - | -16.75 % | $ 25.8 M | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
9.38 M | - | - | $ 231 M | USA |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Cardiff Oncology
CRDF
|
16.5 M | $ 1.74 | 0.29 % | $ 116 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
123 M | - | - | $ 2.18 B | USA |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
389 M | - | - | $ 2.02 B | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Editas Medicine
EDIT
|
159 M | $ 2.91 | -3.17 % | $ 258 M | USA |
 |
Edesa Biotech
EDSA
|
1.83 M | $ 17.93 | -1.86 % | $ 57.3 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 2.95 | -7.52 % | $ 4.86 M | Israel |
 |
Eiger BioPharmaceuticals
EIGR
|
53.3 M | - | -9.21 % | $ 2.55 M | USA |
 |
Eloxx Pharmaceuticals
ELOX
|
31.8 M | - | -5.68 % | $ 8.28 M | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Ampio Pharmaceuticals
AMPE
|
2.38 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Evogene Ltd.
EVGN
|
8.07 M | $ 0.78 | - | $ 27.9 M | Israel |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |